ClinicalTrials.gg
CompletedNCT04405739Updated Mar 23, 2023Results posted

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

A Phase 2 interventional study of EIDD-2801 and Placebo in SARS-CoV 2, sponsored by Ridgeback Biotherapeutics, LP. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Ridgeback Biotherapeutics, LP · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.

Read the detailed description

Phase 2a randomized, placebo-controlled, double-blinded clinical trial of EIDD-2801 (also known as MK 4482) in adult men and women who have tested positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection by polymerase chain reaction (PCR) test within 6 days (144 hours) prior to randomization and are hospitalized with a diagnosis of COVID-19. Rapid enrollment and treatment will be initiated such that the first dose of EIDD-2801 or placebo will be administered as soon as possible and within 7 days of onset of symptoms.

02

Conditions studied

  • SARS-CoV 2
03

In context

Lead sponsor

Ridgeback Biotherapeutics, LP is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has COVID-19 disease, defined by having one or more of the following new symptoms and signs (within 7 days):

    • Fevers OR
    • At least one of the following symptoms: cough, shortness of breath, respiratory rate ≥ 20, radiographic evidence of pneumonia OR
    • Anosmia OR
    • other clinical symptoms or signs of COVID-19 that are not otherwise explained by comorbidities or co-diagnoses
  2. PCR+ test for SARS-CoV-2.
  3. Has new signs or symptoms of COVID-19 that began ≤7 days of anticipated first dose of study drug.
  4. Persons ≥18 years old.
  5. at the time of first dose.
  1. ≥18 years old.
  1. Is willing and able to comply with all study procedures including providing , collection of virology samples, and any safety tests that are not included as part of standard of care (SOC).
  1. Is willing and able to take oral medications, and is anticipated to be able to take the full course of 5 days of study drug.

Pregnancy and : In nonclinical developmental and reproductive toxicity studies, developmental toxicity including malformation was observed in fetuses from pregnant animals dosed with EIDD-2801 (MK 4482). Therefore, treatment with EIDD-2801 is in women who are pregnant or nursing and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during the study and for 4 days after completion of EIDD 2801 dosing in female participants and for 4 days after completion of EIDD-2801 dosing in female partners of male participants.

  1. A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:
  • Is not a woman of (WOCBP) OR
  • Is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user-dependent method in combination with a barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 2 during the intervention period and for at least 4 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention.
  • A WOCBP must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention.
  • Additional requirements for pregnancy testing during and after study intervention are located in Section 4.4.
  • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Given the elevated risk of venous thrombotic events in patients hospitalized with COVID 19 (Benson et al 2020; Spratt et al 2020), estrogen-containing contraceptives must not be started to fulfill the contraceptive requirement of this study at any time during participant's hospitalization. If contraceptives are interrupted as standard of care management of COVID-19 patients and resumed at a later time point, such as at hospital discharge, then abstinence must be practiced for the defined period of back-up contraception per the contraceptive product labeling. After this period, contraceptive use must adhere to Appendix 2.

    1. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 4 days after the last dose of study intervention:
  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
  • Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause [Appendix 2]) as detailed below:

Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.

  • Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  1. Is anticipated to require ICU admission for mechanical ventilation within 24 hours of enrollment.
  2. Requires more than 6 liters/minute of oxygen to maintain O2 saturation above 95%
  3. Is not expected to survive longer than 24 hours.
  4. Has a count less than 100,000/µL, less than 9 g/dL, or has a disorder of the hematologic system including anemic disorder or other blood dyscrasia, cancer of the hematologic system, history of bone marrow transplant, or other significant hematologic disease.
  5. Women who are pregnant or breastfeeding.
  6. Is experiencing DAIDS AE grading scale grade 4 baseline medical conditions or laboratory abnormalities..
  7. Has received a vaccine for COVID-19 prior to enrollment, or plans to receive a vaccine for COVID-19 before the end-of-study visit.
  8. Has received an experimental antiviral treatment for COVID-19 prior to enrollment.
  9. Has received convalescent plasma or other monoclonal antibodies prior to enrollment..
  10. Is participating in another clinical study that involves pharmacologic intervention or has participated in another study within 30 days of 5 half-lives of the agent (observational study participation is permitted).
  11. In the opinion of the investigator, has end-organ disease as a result of relevant comorbidities: chronic kidney disease (reduced (GFR) \<30 mL/min by the Modification of Diet in Renal Disease (MDRD) study equation prior to COVID-19 symptom onset), decompensated chronic liver disease or cirrhosis, decompensated congestive heart failure, active peripheral vascular disease including active diabetic ulcers, chronic pulmonary disease prior to COVID-19 symptom onset requiring bilevel positive airway pressure (BiPAP) or >4 L/min supplemental oxygen at baseline; if using ≤4 L/min supplemental oxygen at baseline, consultation with and approval of the sponsor is required prior to enrollment.
  12. Has a diagnosis of cancer that is not in remission. Noninvasive cancers, such as basal and squamous cell carcinoma or history of in situ tumors are allowed at the discretion of the investigator after discussion with the sponsor.
  13. Has received an organ transplantation.
  14. Has received a bone marrow transplantation.
  15. Has been on medications within one month prior to enrollment.
  16. Has any condition that would, in the opinion of the investigator, put the participant at increased risk for participation in a clinical trial.
  17. Has known active (HCV RNA positive), active (hepatitis B surface antigen positive), or (ELISA and confirmatory Western blotting). New screening tests not required.
  18. Is currently taking nucleos(t)ide analogues for HIV or Hepatitis B, or for their prevention, within 30 days of study enrollment.
  19. Is currently taking systemic other than replacement doses, or for treatment of COVID-19.
  20. Has a (BMI) >50 kg/m2.
  21. Is anticipated to require surgery within 48 hours after hospital admission.
  22. Is anticipated to have a nothing per mouth (NPO) order placed within 48 hours after hospital admission that is expected to last for > 24 hours.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    EIDD-2801 twice daily (BID) for 5 days

    EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F

    Drug: EIDD-2801

  • Placebo comparator
    placebo (PBO) twice daily (BID) for 5 days

    Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP

    Drug: Placebo

Interventions

  • Oral capsule of EIDD-2801

    Also known as: molnupiravir, MK-4482

  • DrugPlacebo

    Oral placebo capsule

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801

    Achievement of undetectable (below the limit of detection of the assay) SARS-CoV-2 RNA by day 5 in NP swabs by quantitative Polymerase Chain Reaction (qPCR) in the Efficacy Analysis Set (EAS). The Efficacy Analysis Set consisted of all participants treated with at least on dose of study drug and with at least 1 post baseline assessment of SARS-CoV-2 RNA in NP swabs by qPCR

    Time frame: 28 days

  2. Number of Participants With Any Serious Adverse Events(SAEs) as Assessed by DAIDS

    Incidence of Serious Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS in the Safety Population, defined as all participants treated with at least one dose of study drug.

    Time frame: 28 days

  3. Number of Participants With Any Adverse Events(AEs) as Assessed by DAIDS

    Incidence of Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS

    Time frame: 28 days

07

Results

Posted Mar 23, 2023

Participant flow

Participant flow — Overall Study
MilestoneMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Started4182524
Completed4132218
Not completed0536
Withdrew: Adverse event0100
Withdrew: Lost to follow-up0213
Withdrew: Withdrawal by subject0211
Withdrew: Death0010
Withdrew: Transferred to rehab0001
Withdrew: Pt. refused ip after 1 dose0001

Outcome measures

PrimaryNumber of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801

Achievement of undetectable (below the limit of detection of the assay) SARS-CoV-2 RNA by day 5 in NP swabs by quantitative Polymerase Chain Reaction (qPCR) in the Efficacy Analysis Set (EAS). The Efficacy Analysis Set consisted of all participants treated with at least on dose of study drug and with at least 1 post baseline assessment of SARS-CoV-2 RNA in NP swabs by qPCR

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801
ParticipantsMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-280104107
PrimaryNumber of Participants With Any Serious Adverse Events(SAEs) as Assessed by DAIDS

Incidence of Serious Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS in the Safety Population, defined as all participants treated with at least one dose of study drug.

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Events(SAEs) as Assessed by DAIDS
ParticipantsMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Number of Participants With Any Serious Adverse Events(SAEs) as Assessed by DAIDS0013
PrimaryNumber of Participants With Any Adverse Events(AEs) as Assessed by DAIDS

Incidence of Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events(AEs) as Assessed by DAIDS
ParticipantsMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Number of Participants With Any Adverse Events(AEs) as Assessed by DAIDS4111215

Adverse events

Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Molnupiravir 200 mg0/4 (0%)0/4 (0%)4/4 (100%)
Molnupiravir 400 mg0/18 (0%)0/18 (0%)11/18 (61.1%)
Molnupiravir 800 mg1/25 (4%)1/25 (4%)8/25 (32%)
Placebo0/24 (0%)3/24 (12.5%)12/24 (50%)
Most frequent serious events
Most frequent serious events
EventMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
HypotensionVascular disorders0/40/180/251/24
Non-cardiac chest painGeneral disorders0/40/180/251/24
BradycardiaCardiac disorders0/40/180/251/24
DehydrationMetabolism and nutrition disorders0/40/180/251/24
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/40/181/250/24
Hypovolemic shockVascular disorders0/40/181/250/24
Most frequent other events
Showing 10 of 28
Most frequent other events
EventMolnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlacebo
Blood glucose increasedInvestigations2/41/181/252/24
NauseaGastrointestinal disorders1/42/180/250/24
Abdominal discomfortGastrointestinal disorders1/40/180/250/24
Blood pressure increasedInvestigations1/40/180/251/24
Heart rate increasedInvestigations1/40/180/250/24
HypoxiaRespiratory, thoracic and mediastinal disorders1/40/183/252/24
AstheniaGeneral disorders1/40/180/250/24
HyperglycemiaMetabolism and nutrition disorders1/41/181/251/24
DehydrationMetabolism and nutrition disorders1/41/180/253/24
AgeusiaNervous system disorders1/40/180/250/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Mean56.3 ± 9.0752.1 ± 16.3753.5 ± 15.4257.1 ± 14.4354.5 ± 14.93
Sex: Female, Male
Sex: Female, Male(Participants)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Female06111128
Male412141343
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Hispanic or Latino11011830
Not Hispanic or Latino38141641
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
American Indian or Alaska Native00000
Asian00213
Black or African American227415
White17121434
Unknown/Not reported01012
Other173415
More than one race01102
Native Hawaiian or Other Pacific Islander00000
SARS-CoV-2 RNA by qPCR in NP Swabs
SARS-CoV-2 RNA by qPCR in NP Swabs(log 10 copies/mL)Molnupiravir 200 mgMolnupiravir 400 mgMolnupiravir 800 mgPlaceboTotal
Mean6.45 ± 1.6554.83 ± 1.4874.77 ± 1.4425.07 ± 1.5535.24 ± 0.42
08

Study locations

11 sites
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095-8358, United States
  • Cook County Hospital
    Chicago, Illinois 60612, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • Advocate Lutheran General Hospital
    Park Ridge, Illinois 60068, United States
  • Ochsner LSU Health Shreveport Academic Medical Center
    Shreveport, Louisiana 71101, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Howard County General Hospital
    Columbia, Maryland 21044, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Vanderbilt University
    Nashville, Tennessee 37235, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021 Jan;6(1):11-18. doi: 10.1038/s41564-020-00835-2. Epub 2020 Dec 3. PubMed 33273742 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Feb 2022, 20 months.

Results were first posted in Mar 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
May 28, 2020
StartActual
Jun 16, 2020
Primary completionActual
Feb 21, 2022
CompletionActual
Feb 21, 2022
Results first posted
Mar 23, 2023
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04405739
Lead sponsor
Ridgeback Biotherapeutics, LP
Responsible party
Sponsor
First posted
May 28, 2020
Start date
Jun 16, 2020
Primary completion
Feb 21, 2022
Completion
Feb 21, 2022
Results posted
Mar 23, 2023
Last update
Mar 23, 2023

Study contacts

Ashwin Balagopal, MD
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion